Lantern Pharma (LTRN) Scheduled to Post Quarterly Earnings on Thursday

Lantern Pharma (NASDAQ:LTRN) is set to announce its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Lantern Pharma (NASDAQ:LTRN) last issued its quarterly earnings results on Monday, March 18th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.01. On average, analysts expect Lantern Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Lantern Pharma Stock Performance

NASDAQ:LTRN opened at $6.42 on Wednesday. The stock has a 50-day simple moving average of $6.96 and a 200 day simple moving average of $4.94. Lantern Pharma has a one year low of $2.38 and a one year high of $11.99. The company has a market capitalization of $69.08 million, a price-to-earnings ratio of -4.34 and a beta of 1.57.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “neutral” rating on shares of Lantern Pharma in a research report on Thursday, April 25th.

Insider Buying and Selling

In other Lantern Pharma news, major shareholder Aaron G.L. Fletcher sold 74,297 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $4.85, for a total transaction of $360,340.45. Following the completion of the transaction, the insider now directly owns 62,088 shares of the company’s stock, valued at approximately $301,126.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 6.92% of the company’s stock.

About Lantern Pharma

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.